Barclays PLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 42.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,166 shares of the company's stock after acquiring an additional 8,385 shares during the quarter. Barclays PLC owned 0.09% of Medpace worth $9,359,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Lindbrook Capital LLC raised its position in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC grew its stake in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. Proficio Capital Partners LLC lifted its stake in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after acquiring an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its holdings in Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after acquiring an additional 30 shares during the period. 77.98% of the stock is currently owned by institutional investors.
Medpace Stock Performance
Shares of NASDAQ:MEDP opened at $282.28 on Wednesday. The firm has a market capitalization of $8.53 billion, a P/E ratio of 22.35, a P/E/G ratio of 3.81 and a beta of 1.46. The stock has a 50 day moving average price of $316.36 and a 200-day moving average price of $332.53. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same quarter in the prior year, the company earned $3.20 earnings per share. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Wall Street Analyst Weigh In
MEDP has been the subject of several recent research reports. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Mizuho lowered their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Truist Financial cut their target price on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $357.50.
Get Our Latest Stock Report on MEDP
Medpace Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Recommended Stories
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
